# Trust & Completeness Pass — Batch 1

Date: 2026-07-15

Status: Applied
Branch: `agent/trust-completeness-batch-1`

## Outcome

Batch 1 completed the Trust & Completeness Pass for 25 of the 50 safety-reviewed compound profiles. Each profile now publishes its reviewed safety evidence through the existing `runtime_safety` field, including a concise evidence-strength label. Compound pages use that reviewed field to show a separate “Who should avoid this?” summary and contextual “Talk to a healthcare professional if…” guidance without converting evidence gaps into medical claims.

## Compounds completed

1. `probiotics`
2. `probiotic-multistrain`
3. `probiotic-strain-bifidobacterium`
4. `probiotic-strain-lactobacillus`
5. `probiotics-bifidobacterium`
6. `probiotics-lactobacillus`
7. `aged-garlic-extract`
8. `garlic-aged-extract`
9. `artichoke-extract`
10. `betaine`
11. `betaine-anhydrous`
12. `trimethylglycine`
13. `beetroot-nitrate`
14. `taurine-sleep`
15. `holy-basil-extract`
16. `pomegranate-extract`
17. `ginkgolide-b`
18. `ginkgolides`
19. `gingerol`
20. `gingerols`
21. `glycine-sleep`
22. `inositol-sleep`
23. `eaa-blend`
24. `electrolyte-blend`
25. `taurine-blend`

## Trust improvements

- Added 25 source-backed runtime safety entries to the workbook and generated public data.
- Added concise safety evidence labels that distinguish systematic-review, regulatory, limited-human, and formulation-specific evidence.
- Added a “Who should avoid this?” summary that uses documented contraindications only; medication interactions remain separate.
- Added conditional provider guidance for documented medication, pregnancy, surgery, and health-condition concerns.
- Added an explicit evidence-limited blank state: lack of a documented contraindication is not presented as established safety.
- Preserved existing efficacy evidence tiers, schema, routes, and article content.

## Evidence limitations

Evidence strength describes the available safety evidence for the exact profile or the closest supported formulation. It is not a claim that a compound is safe for every person or use. Formulation-specific rows do not inherit unsupported warnings from related ingredients, and profiles without an evidence-backed contraindication retain an explicit uncertainty statement.

## Audit progress

| Metric | Before pass | After Batch 1 |
|---|---:|---:|
| Safety-reviewed profiles in scope | 50 | 50 |
| Trust-complete profiles | 0 | 25 |
| Remaining trust profiles | 50 | 25 |
| Trust validation errors | 0 | 0 |
| Remaining actionable safety gaps | 0 | 0 |

## Principal evidence

The workbook patch records the complete evidence notes and identifiers. Sources reused from the completed safety review include systematic reviews, regulatory assessments, and human trials for probiotics, aged garlic, artichoke, betaine, beetroot nitrate, holy basil, pomegranate, ginkgo constituents, and ginger constituents. Additional formulation-row sources include:

- Glycine systematic review: DOI `10.1007/s11357-023-00970-8`
- Inositol guideline review: DOI `10.1210/clinem/dgad762`
- Essential amino acid/protein perioperative review: DOI `10.7759/cureus.69212`
- Electrolyte rehydration systematic review: DOI `10.4085/1062-6050-0682.22`
- Taurine metabolic-syndrome meta-analysis: DOI `10.1038/s41387-024-00289-z`

## Validation

- Workbook patch validation: passed (25 changes)
- Workbook schema validation: passed (881 rows, 52 columns)
- Workbook round-trip test: passed (22 sheets preserved)
- Core data build: passed
- Trust completeness audit: passed (25 complete, 25 remaining, 0 errors)
- Strict safety audit: passed (0 actionable full-public gaps)
- Targeted trust and workbook-reader tests: passed (5 tests)
- TypeScript: passed
- ESLint: passed with zero warnings
- Vitest: passed (97 files, 606 tests)
- Production static-export build: passed (20 deploy steps, 1,187 static pages)

## Next priority

Complete the remaining 25 safety-reviewed profiles in Batch 2, then rerun the trust audit at 50 of 50.
